Wanjia Group Holdings Limited (HKG:0401)

Revenue by Segment

Financials in millions HKD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Pharmaceutical Wholesale and Distribution Business	55.32M	50.49M	51.54M	52.28M	51.18M
Pharmaceutical Wholesale and Distribution Business Growth	9.57%	-2.03%	-1.42%	2.14%	-12.91%
Hemodialysis Treatment and Consultancy Service Business	110.06M	111.20M	129.56M	121.42M	103.64M
Hemodialysis Treatment and Consultancy Service Business Growth	-1.02%	-14.17%	6.70%	17.16%	87.36%
Total	165.39M	161.69M	181.09M	173.70M	154.82M
Total Growth	2.28%	-10.71%	4.25%	12.19%	35.71%

Revenue by Geography

Financials in millions HKD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
People's Republic of China (PRC)	165.39M	161.69M	181.09M	173.70M	154.82M
People's Republic of China (PRC) Growth	2.28%	-10.71%	4.25%	12.19%	35.71%
Total	165.39M	161.69M	181.09M	173.70M	154.82M
Total Growth	2.28%	-10.71%	4.25%	12.19%	35.71%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 10, 2026

Data Sources Report a data error